Read on Twitter
#CollinsConclusions -DLBCL1
Drugs v cells:
• bispecifics come of age
- CRR~ 50% DLBCL
- step up dosing & subcut
CRS
- 1L elderly safe & active
- v little neurotox
• CART
- 1L high risk DLBCL 75% CR
- dual Ag targeting looks v active
- durability of CRs on longer FU
#ASH2020
Drugs v cells:
• bispecifics come of age
- CRR~ 50% DLBCL
- step up dosing & subcut
CRS- 1L elderly safe & active
- v little neurotox
• CART
- 1L high risk DLBCL 75% CR
- dual Ag targeting looks v active
- durability of CRs on longer FU
#ASH2020
#CollinsConclusion -DLBCL2
CNS proph proves controversial
• 2x retrosp studies show no benefit for IV MTX
• but some issues with the analyses
• 3 reactions:
- doesn’t work so give nothing
- give more (or new agents)
- carry on giving to high CNS IPI
Which are you? #ASH20
CNS proph proves controversial
• 2x retrosp studies show no benefit for IV MTX
• but some issues with the analyses
• 3 reactions:
- doesn’t work so give nothing
- give more (or new agents)
- carry on giving to high CNS IPI
Which are you? #ASH20
#CollinsConclusions -DLBCL3
Actually Burkitt!
• new BL-IPI defined
• age 40+, LDH >3xULN, PS 2-4, CNS involvement
• RCODOX-M & DA-EPOCHR fairly equiv
• HIV not an adverse risk factor
Now just need to work out how to improve cure for high risk & reduce intensity for low #ASH20
Actually Burkitt!
• new BL-IPI defined
• age 40+, LDH >3xULN, PS 2-4, CNS involvement
• RCODOX-M & DA-EPOCHR fairly equiv
• HIV not an adverse risk factor
Now just need to work out how to improve cure for high risk & reduce intensity for low #ASH20
#CollinsConclusions -DLBCL4
Some interesting CHOP+X studies
• ACCEPT (RCHOP+acala), could this make Phoenix rise from the ashes - keep benefit but less tox?
• avelumabR prior to chemo - surprisingly high ORR; is giving PDL1i prior to chemo the right place?
#ASH20
Some interesting CHOP+X studies
• ACCEPT (RCHOP+acala), could this make Phoenix rise from the ashes - keep benefit but less tox?
• avelumabR prior to chemo - surprisingly high ORR; is giving PDL1i prior to chemo the right place?
#ASH20
#CollinsConclusion -DLBCL5
No major randomised trials presented this year. Polarix hotly awaited! Controversy around CNSL proph highlights need for international cooperative prospective studies. So much happening in DLBCL - v exciting time to be involved. #ASH20
No major randomised trials presented this year. Polarix hotly awaited! Controversy around CNSL proph highlights need for international cooperative prospective studies. So much happening in DLBCL - v exciting time to be involved. #ASH20
Thanks to @DrChrisPFox @wendster, Andy Davies, Kim Linton, @CwynKate, @lymphomatic, George Follows, @tobyeyre82 @chanyooncheah @DrElizaHawkes @DrAEvens @chadinabhan & many others for discussion of data, helpful tweets and views. #ASH20
